Greenwood Gearhart Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 0.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 160,821 shares of the biopharmaceutical company’s stock after purchasing an additional 65 shares during the quarter. Pfizer comprises 2.1% of Greenwood Gearhart Inc.’s investment portfolio, making the stock its 26th largest holding. Greenwood Gearhart Inc.’s holdings in Pfizer were worth $5,402,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. K.J. Harrison & Partners Inc grew its stake in shares of Pfizer by 11.9% during the 1st quarter. K.J. Harrison & Partners Inc now owns 48,639 shares of the biopharmaceutical company’s stock worth $1,664,000 after purchasing an additional 5,159 shares during the period. Callahan Advisors LLC grew its stake in shares of Pfizer by 1.9% during the 1st quarter. Callahan Advisors LLC now owns 279,334 shares of the biopharmaceutical company’s stock worth $9,556,000 after purchasing an additional 5,176 shares during the period. Beaumont Financial Partners LLC grew its stake in shares of Pfizer by 17.1% during the 1st quarter. Beaumont Financial Partners LLC now owns 8,597 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 1,254 shares during the period. Grandfield & Dodd LLC grew its stake in shares of Pfizer by 0.3% during the 1st quarter. Grandfield & Dodd LLC now owns 83,230 shares of the biopharmaceutical company’s stock worth $2,847,000 after purchasing an additional 250 shares during the period. Finally, Usca Ria LLC grew its stake in shares of Pfizer by 19.6% during the 1st quarter. Usca Ria LLC now owns 331,931 shares of the biopharmaceutical company’s stock worth $11,355,000 after purchasing an additional 54,492 shares during the period. Hedge funds and other institutional investors own 69.89% of the company’s stock.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.61 EPS. equities analysts predict that Pfizer Inc. will post 2.59 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.50%. Pfizer’s payout ratio is currently 79.01%.
PFE has been the topic of a number of recent analyst reports. Barclays set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 11th. BMO Capital Markets set a $37.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, October 10th. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Tuesday, October 3rd. Finally, Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company. Pfizer has an average rating of “Buy” and an average price target of $38.77.
TRADEMARK VIOLATION NOTICE: “Greenwood Gearhart Inc. Grows Position in Pfizer Inc. (PFE)” was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/13/greenwood-gearhart-inc-grows-position-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
What are top analysts saying about Pfizer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer and related companies.